# A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors

> **NCT03312842** · PHASE1 · COMPLETED · sponsor: **CStone Pharmaceuticals** · enrollment: 259 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** CS1001

## Key facts

- **NCT ID:** NCT03312842
- **Lead sponsor:** CStone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-19
- **Primary completion:** 2021-08-16
- **Final completion:** 2022-02-16
- **Target enrollment:** 259 (ACTUAL)
- **Last updated:** 2022-05-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03312842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03312842, "A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03312842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*